Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

ClinicalTrials.gov ID: NCT03548987

Public ClinicalTrials.gov record NCT03548987. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 4:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity Who Have Reached Target Dose During run-in Period

Study identification

NCT ID
NCT03548987
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
902 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • Semaglutide Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 3, 2018
Primary completion
Feb 21, 2020
Completion
Mar 19, 2020
Last update posted
Jan 18, 2022

2018 – 2020

United States locations

U.S. sites
28
U.S. states
15
U.S. cities
25
Facility City State ZIP Site status
Novo Nordisk Investigational Site Anniston Alabama 36207
Novo Nordisk Investigational Site Fresno California 93720
Novo Nordisk Investigational Site San Diego California 92108
Novo Nordisk Investigational Site Alpharetta Georgia 30022
Novo Nordisk Investigational Site Roswell Georgia 30076
Novo Nordisk Investigational Site Suwanee Georgia 30024
Novo Nordisk Investigational Site Louisville Kentucky 40213
Novo Nordisk Investigational Site Baton Rouge Louisiana 70808
Novo Nordisk Investigational Site Elkridge Maryland 21075-6437
Novo Nordisk Investigational Site Buckley Michigan 49620
Novo Nordisk Investigational Site Omaha Nebraska 68198-3020
Novo Nordisk Investigational Site New York New York 10016
Novo Nordisk Investigational Site Greensboro North Carolina 27408
Novo Nordisk Investigational Site Greenville North Carolina 27834
Novo Nordisk Investigational Site Raleigh North Carolina 27612
Novo Nordisk Investigational Site Salisbury North Carolina 28144
Novo Nordisk Investigational Site Cincinnati Ohio 45242
Novo Nordisk Investigational Site Dayton Ohio 45406
Novo Nordisk Investigational Site Bristol Tennessee 37620-7352
Novo Nordisk Investigational Site Bristol Tennessee 37620
Novo Nordisk Investigational Site Chattanooga Tennessee 37404
Novo Nordisk Investigational Site Austin Texas 78731
Novo Nordisk Investigational Site Dallas Texas 75226
Novo Nordisk Investigational Site Dallas Texas 75230
Novo Nordisk Investigational Site Dallas Texas 75231
Novo Nordisk Investigational Site Arlington Virginia 22206
Novo Nordisk Investigational Site Richmond Virginia 23226
Novo Nordisk Investigational Site Wenatchee Washington 98801-2028

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 44 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03548987, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 18, 2022 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03548987 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →